Hernando, C.; Ortega-Morillo, B.; Tapia, M.; Moragón, S.; MartÃnez, M.T.; Eroles, P.; Garrido-Cano, I.; Adam-Artigues, A.; Lluch, A.; Bermejo, B.;
et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22, 7812.
https://doi.org/10.3390/ijms22157812
AMA Style
Hernando C, Ortega-Morillo B, Tapia M, Moragón S, MartÃnez MT, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B,
et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. International Journal of Molecular Sciences. 2021; 22(15):7812.
https://doi.org/10.3390/ijms22157812
Chicago/Turabian Style
Hernando, Cristina, Belén Ortega-Morillo, Marta Tapia, Santiago Moragón, MarÃa Teresa MartÃnez, Pilar Eroles, Iris Garrido-Cano, Anna Adam-Artigues, Ana Lluch, Begoña Bermejo,
and et al. 2021. "Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective" International Journal of Molecular Sciences 22, no. 15: 7812.
https://doi.org/10.3390/ijms22157812
APA Style
Hernando, C., Ortega-Morillo, B., Tapia, M., Moragón, S., MartÃnez, M. T., Eroles, P., Garrido-Cano, I., Adam-Artigues, A., Lluch, A., Bermejo, B., & Cejalvo, J. M.
(2021). Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. International Journal of Molecular Sciences, 22(15), 7812.
https://doi.org/10.3390/ijms22157812
